LYKA LABS
|
LYKA LABS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -4.30 | 13.59 | -4.03 | -21.10 | -1.97 |
| CEPS(Rs) | 0.32 | 19.45 | -0.62 | -19.03 | 0.34 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 9.12 | 4.65 | -8.99 | -5.00 | 15.02 |
| Tax Rate(%) | 0.14 | 35.11 | 28.66 | -1.20 | 58.82 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.09 | 52.12 | 22.82 | -5.97 | -2.68 |
| EBIT Margin(%) | -1.40 | 40.90 | 13.67 | -68.00 | -11.67 |
| Pre Tax Margin(%) | -14.15 | 30.53 | -16.40 | -100.63 | -21.79 |
| PAT Margin (%) | -14.13 | 19.81 | -11.70 | -101.84 | -8.97 |
| Cash Profit Margin (%) | 1.07 | 28.75 | -2.05 | -88.81 | 1.36 |
| Performance Ratios | |||||
| ROA(%) | -7.80 | 21.40 | -5.58 | -32.05 | -2.97 |
| ROE(%) | -63.63 | - | - | -448.65 | -14.20 |
| ROCE(%) | -1.00 | 56.68 | 8.95 | -31.39 | -5.50 |
| Asset Turnover(x) | 0.55 | 1.08 | 0.48 | 0.31 | 0.33 |
| Sales/Fixed Asset(x) | 0.56 | 1.02 | 0.44 | 0.31 | 0.40 |
| Working Capital/Sales(x) | 8.02 | -4.12 | -4.15 | -2.02 | -1.42 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.80 | 0.98 | 2.27 | 3.18 | 2.53 |
| Receivable days | 75.65 | 25.51 | 35.37 | 67.29 | 90.56 |
| Inventory Days | 29.71 | 11.76 | 23.36 | 40.77 | 46.92 |
| Payable days | 104.00 | 92.01 | 161.35 | 223.12 | 220.61 |
| Valuation Parameters | |||||
| PER(x) | - | 9.98 | - | - | - |
| PCE(x) | 322.97 | 6.97 | -42.22 | -0.67 | 71.67 |
| Price/Book(x) | 11.47 | 29.17 | -2.89 | -2.55 | 1.63 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 4.10 | 2.59 | 2.66 | 2.73 | 2.31 |
| EV/Core EBITDA(x) | 18.86 | 4.86 | 10.82 | -289.15 | 854.63 |
| EV/EBIT(x) | -293.50 | 6.33 | 19.49 | -4.01 | -19.82 |
| EV/CE(x) | 2.52 | 2.71 | 1.32 | 0.89 | 0.81 |
| M Cap / Sales | 3.45 | 2.00 | 0.86 | 0.59 | 0.97 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -52.05 | 125.02 | 40.27 | -13.13 | 18.35 |
| Core EBITDA Growth(%) | -80.40 | 385.97 | 3,765.48 | -402.66 | 113.51 |
| EBIT Growth(%) | -101.64 | 573.04 | 128.21 | -406.23 | 21.07 |
| PAT Growth(%) | -134.21 | 480.98 | 83.89 | -885.87 | 66.58 |
| EPS Growth(%) | -131.67 | 437.53 | 80.91 | -969.89 | 67.76 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 2.58 | 9.76 | -6.30 | -9.85 | 2.28 |
| Current Ratio(x) | 1.36 | 0.53 | 0.58 | 0.54 | 0.41 |
| Quick Ratio(x) | 1.14 | 0.44 | 0.50 | 0.44 | 0.34 |
| Interest Cover(x) | -0.11 | 3.94 | 0.45 | -2.08 | -1.15 |
| Total Debt/Mcap(x) | 0.22 | 0.33 | 2.18 | 3.86 | 1.40 |
Compare Financial Ratios of peers of LYKA LABS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| LYKA LABS | ₹422.5 Cr | -2.3% | -13.8% | 4% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹369,402.0 Cr | 3% | 2.3% | 68.2% | Stock Analytics | |
| CIPLA | ₹109,341.0 Cr | 2.5% | 0.4% | 71.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,341.0 Cr | -0.2% | -4.9% | 40.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹99,176.4 Cr | -1.6% | -7% | 23.8% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹96,543.1 Cr | 5% | 10.4% | 109.1% | Stock Analytics | |
LYKA LABS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LYKA LABS | -2.3% |
-13.8% |
4% |
| SENSEX | -0.8% |
1.4% |
22.9% |
You may also like the below Video Courses
